Azelastine

Research use only, not for human use.

Azelastine is a potent, second-generation, selective, histamine antagonist.

Azelastine is a potent, second-generation, selective, histamine antagonist.

Azelastine can significantly inhibit HNEpC proliferation, and therefore, be helpful in against airway remodeling.Cell Proliferation Assay Cell Line:Human nasal epithelial cells (HNEpC)Concentration:100 μM, 400 μM Incubation Time:21 days Result:Inhibited HNEpC growth.Western Blot Analysis Cell Line:Human nasal epithelial cells (HNEpC) Concentration:100 μM Incubation Time:7 days Result:Significantly up-regulated the H1R, M1R and M3R levels.

Azelastine (4 mg/kg; p.o.; daily; for 8 weeks) significantly reduces blood glucose, HbA1c and serum alkaline phosphatase (ALP), osteocalcin and downregulates apolipoprotein B in diabetic hyperlipidemic rats model.Azelastine (4 mg/kg; p.o.; daily; for 8 weeks) improves the lipid profile (LDL-c decrease and HDL-c increase) in diabetic hyperlipidemic rats model.Azelastine (4 mg/kg; p.o.; daily; for 8 weeks) attenuates calcium deposition and aortic calcification in diabetic hyperlipidemic rats model. Animal Model:Male albino Wistar rats (150-170 g), diabetic hyperlipidemic rats modelDosage:4 mg/kg Administration:Oral administration, daily, for 8 weeks Result:Ameliorated aortic calcification and increased apolipoprotein A expression along with a decline in apolipoprotein B.

——

GPCR/G Protein

Histamine Receptor

H1 receptor

Inflammation/Immunology

——

58581-89-8

381.9

C22H24ClN3O

>98% (HPLC)

Soluble in DMSO

CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O

——

(-20℃)

With Ice Pack

≥ 2 years